Eyevance Pharmaceuticals has acquired worldwide licensing rights to Nexagon, a 30-base antisense oligomer treatment candidate for persistent corneal epithelial defect, according to a press release.
A worldwide licensing agreement with OcuNexus Therapeutics will allow Eyevance to continue development of Nexagon, an unmodified antisense oligodeoxynucleotide that inhibits a cell membrane hemichannel forming protein and re-establishes limbal microvasculature, promoting regeneration of the corneal epithelium, the release said.
The company is funding a pivotal clinical trial that is expected to start
Uncategorized